22.07.2011 • News

Syngenta H1 Profit Up

Syngenta reported a 14% rise in its first-half net income attributable to the company's shareholders to $1.43 billion from $1.25 billion last year. Excluding restructuring and impairment, quarterly earnings per share were $15.60, higher than $13.95 in the year earlier period.

The company reported first-half sales of $7.7 billion, up 14% from $6.74 billion in the comparable period a year ago. Sales at constant exchange rates or CER increased by 12%.

Mike Mack, chief executive, noted, "We expect to generate 2011 full year free cash flow in excess of $1 billion.

In addition, the outlook for pricing for the rest of the year is positive and we expect stable pricing for the full year. For the 2012 season, we are currently raising prices across the business with the aim of achieving an overall increase in the mid single digits."

 

Company

Syngenta International AG


Basel
Switzerland

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read